CLINICAL EFFICACY OF RIZENDRONATE ACID IN THE COMPLEX THERAPY OF PATIENTS WITH OSTEOARTHRITIS AND METABOLIC SYNDROME
https://doi.org/10.21886/2219-8075-2017-1-65-69
Abstract
Objective: to assess the impact rizendronate acid on clinical and laboratory flow pattern of osteoarthritis in patients with the metabolic syndrome.
Material and methods: the study included 50 patients with osteoarthritis and metabolic syndrome, which on the background of pathogenetic therapy received rizendronate acid at 35 mg per week during the year. Patients were evaluated indicators of inflammatory activity (ESR, CRP, TNF-α). The severity of articular syndrome was interpreted on a scale in rest and during movement, Lequesne index and WOMAC initially and after 3, 6 and 12 months. Mineral bone density (BMD) was assessed at lumbar spine by carrying out dual energy x-ray absorptiometry.
Results: among patients receiving rizendronate acid was recorded a significant decline in CRP, ESR, TNF-α, positive changes in the indicators of the articular status – a significant reduction in the severity of pain at rest and in motion, decrease in Lequesne and WOMAC indexes, the trend of increase in BMD, while reducing the need for non-steroidal anti-inflammatory drugs.
Conclusions: the use of risendronate acid in the complex therapy of patients with osteoarthritis with metabolic syndrome allows to achieve the reduction of the intensity of inflammation, the severity of pain while reducing the need for non-steroidal anti-inflammatory drugs.
About the Authors
D. I. Lakhin
Voronezh State Medical University n. a. N.N. Burdenko
Lipetsk Regional Clinical Hospital
Russian Federation
Russian Federation
10 Studencheskaya st., Voronezh 394036, Russia
6a Moskovskaya st., Lipetsk 398055, Russia
L. V. Vasilyeva
Voronezh State Medical University n. a. N.N. Burdenko
10 Studencheskaya st., Voronezh 394036, Russia
10 Studencheskaya st., Voronezh 394036, Russia
References
1. Dedov II. Obesity. Metabolic syndrome. Diabetes type 2 diabetes. Mosco of metabolic syndrome. Angiology. 2004;55(6):589-612. doi: 10.1177/00033197040550i601
2. Butrova SA. Metabolic syndrome: pathogenesis, clinic, diagnosis, approaches to treatment. Russian Medical Journal. 2001;2:56-60. (In Russ).
3. Rational pharmacotherapy of rheumatic diseases / edited by VA Nasonova, EL Nasonov. Moscow: Litterra, 2003. (In Russ).
4. Rheumatology: national manual / edited by EL Nasonov, VA Nasonova. Moscow: GEOTAR-Media, 2008. (In Russ).
5. Vasilyeva LV, Lakhin DI. Osteoarthritis and metabolic syndrome – a modern vision of the problem. Journal of New Medical Technologies. 2012;9(4):40-43. (In Russ).
6. Droge W. Free radical in the physiological control of cell function. Physiological Reviews. 200282:45-47. doi: 10.1152/physrev.00018.2001
7. Alekseeva LI, Zaytseva EM. Role of subchondral bone in osteoarthritis. Rheumatology Science & Practice. 2009;4:41-48. (In Russ).
8. Westacott CI, Webb GR, Warnock MG, Sims JV, Elson CJ. Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis & Rheumatology. 1997;40(7):1282-1291.
9. International indexes of activity assessment, functional status and quality of life in patients with rheumatic diseases. Moscow: “Association of rheumatologists of Russia”. 2007. (In Russ).
10. Schett G, Zwerina J, David JP. The role of Wnt proteins in arthritis. Nature Clinical Practice Rheumatology. 2008;4(9):473-480. doi: 10.1038/ncprheum0881
11. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis & Rheumatology. 2004; 50(4): 1193-1206. doi: 10.1002/art.20124
12. Bingham CO. Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis & Rheumatology. 2006;54(11):3494-3507. doi: 10.1002/art.22160
13. Papapoulos SE., Schimmer RS. Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Annals of the Rheumatic Disease. 2007;66(7):853-858. doi: 10.1136/ard.2006.064931
Review
For citations:
Lakhin D.I., Vasilyeva L.V. CLINICAL EFFICACY OF RIZENDRONATE ACID IN THE COMPLEX THERAPY OF PATIENTS WITH OSTEOARTHRITIS AND METABOLIC SYNDROME. Medical Herald of the South of Russia. 2017;(1):65-69. (In Russ.) https://doi.org/10.21886/2219-8075-2017-1-65-69
Views:
3762
Email this article 